FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897363011> ?p ?o ?g. }

• W2897363011 abstract "Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis. Gene expression profiling using RNA sequencing was performed in 86 pre-NET and post-NET tumor samples. Targeted next-generation sequencing of 91 candidate breast cancer-associated genes was performed on DNA samples from 89 patients. Molecular data were correlated with radiological response and relapse-free survival. The transcriptional profile of tumors to NET in responders involved immune-associated genes enriched in activated Th1 pathway, which remained unchanged in non-responders. Immune response was confirmed by analysis of tumor-infiltrating lymphocytes (TILs). The percentage of TILs was significantly increased post-NET compared to pre-NET samples in responders (p = 0.0071), but not in non-responders (p = 0.0938). Gene expression revealed that lipid metabolism was the main molecular function related to prognosis, while PPARγ is the most important upstream regulator gene. The most frequently mutated genes were PIK3CA (48.3%), CDH1 (20.2%), PTEN (15.7%), TP53 (10.1%), LAMA2 (10.1%), BRCA2 (9.0%), MAP3K1 (7.9%), ALK (6.7%), INPP4B (6.7%), NCOR1 (6.7%), and NF1 (5.6%). Cell cycle and apoptosis pathway and PIK3CA/AKT/mTOR pathway were altered significantly more frequently in non-responders than in responders (p = 0.0017 and p = 0.0094, respectively). The average number of mutations per sample was significantly higher in endocrine-resistant tumors (2.88 vs. 1.64, p = 0.03), but no difference was observed in terms of prognosis. ESR1 hotspot mutations were detected in 3.4% of treatment-naive tumors. The Th1-related immune system and lipid metabolism appear to play key roles in the response to endocrine therapy and prognosis in HR-positive/HER2-negative breast cancer. Deleterious somatic mutations in the cell cycle and apoptosis pathway and PIK3CA/AKT/mTOR pathway may be relevant for clinical management. This trial is registered with ClinicalTrials.gov ( NCT00629616 ) on March 6, 2008, retrospectively registered." @default.
• W2897363011 created "2018-10-26" @default.
• W2897363011 creator A5005087327 @default.
• W2897363011 creator A5006654386 @default.
• W2897363011 creator A5015082638 @default.
• W2897363011 creator A5015265176 @default.
• W2897363011 creator A5020848251 @default.
• W2897363011 creator A5027696743 @default.
• W2897363011 creator A5031043574 @default.
• W2897363011 creator A5047417830 @default.
• W2897363011 creator A5049797771 @default.
• W2897363011 creator A5060909413 @default.
• W2897363011 creator A5069540694 @default.
• W2897363011 creator A5071952793 @default.
• W2897363011 creator A5073011726 @default.
• W2897363011 creator A5077251700 @default.
• W2897363011 creator A5078203831 @default.
• W2897363011 date "2018-10-11" @default.
• W2897363011 modified "2023-10-14" @default.
• W2897363011 title "Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)" @default.
• W2897363011 cites W1529243395 @default.
• W2897363011 cites W1968587402 @default.
• W2897363011 cites W1979066871 @default.
• W2897363011 cites W1986558653 @default.
• W2897363011 cites W1994703138 @default.
• W2897363011 cites W1995056702 @default.
• W2897363011 cites W2044702943 @default.
• W2897363011 cites W2062510022 @default.
• W2897363011 cites W2078148381 @default.
• W2897363011 cites W2089608754 @default.
• W2897363011 cites W2091673549 @default.
• W2897363011 cites W2096283457 @default.
• W2897363011 cites W2098683355 @default.
• W2897363011 cites W2099920641 @default.
• W2897363011 cites W2101657563 @default.
• W2897363011 cites W2112434826 @default.
• W2897363011 cites W2112780046 @default.
• W2897363011 cites W2120431466 @default.
• W2897363011 cites W2123657823 @default.
• W2897363011 cites W2125885282 @default.
• W2897363011 cites W2134878729 @default.
• W2897363011 cites W2140729960 @default.
• W2897363011 cites W2141458291 @default.
• W2897363011 cites W2146512944 @default.
• W2897363011 cites W2148488946 @default.
• W2897363011 cites W2149441684 @default.
• W2897363011 cites W2153061474 @default.
• W2897363011 cites W2155399095 @default.
• W2897363011 cites W2157650470 @default.
• W2897363011 cites W2159427817 @default.
• W2897363011 cites W2162143298 @default.
• W2897363011 cites W2163860217 @default.
• W2897363011 cites W2168485476 @default.
• W2897363011 cites W2172216132 @default.
• W2897363011 cites W2299167012 @default.
• W2897363011 cites W2301459461 @default.
• W2897363011 cites W2321044145 @default.
• W2897363011 cites W2442565680 @default.
• W2897363011 cites W2463618150 @default.
• W2897363011 cites W2471750430 @default.
• W2897363011 cites W2493364589 @default.
• W2897363011 cites W2560367415 @default.
• W2897363011 cites W2594452323 @default.
• W2897363011 cites W2765486709 @default.
• W2897363011 cites W2767035762 @default.
• W2897363011 cites W2767867768 @default.
• W2897363011 cites W2779681286 @default.
• W2897363011 cites W2782917567 @default.
• W2897363011 cites W779403461 @default.
• W2897363011 doi "https://doi.org/10.1186/s13045-018-0670-9" @default.
• W2897363011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6180434" @default.
• W2897363011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30305115" @default.
• W2897363011 hasPublicationYear "2018" @default.
• W2897363011 type Work @default.
• W2897363011 sameAs 2897363011 @default.
• W2897363011 citedByCount "17" @default.
• W2897363011 countsByYear W28973630112019 @default.
• W2897363011 countsByYear W28973630112020 @default.
• W2897363011 countsByYear W28973630112021 @default.
• W2897363011 countsByYear W28973630112022 @default.
• W2897363011 countsByYear W28973630112023 @default.
• W2897363011 crossrefType "journal-article" @default.
• W2897363011 hasAuthorship W2897363011A5005087327 @default.
• W2897363011 hasAuthorship W2897363011A5006654386 @default.
• W2897363011 hasAuthorship W2897363011A5015082638 @default.
• W2897363011 hasAuthorship W2897363011A5015265176 @default.
• W2897363011 hasAuthorship W2897363011A5020848251 @default.
• W2897363011 hasAuthorship W2897363011A5027696743 @default.
• W2897363011 hasAuthorship W2897363011A5031043574 @default.
• W2897363011 hasAuthorship W2897363011A5047417830 @default.
• W2897363011 hasAuthorship W2897363011A5049797771 @default.
• W2897363011 hasAuthorship W2897363011A5060909413 @default.
• W2897363011 hasAuthorship W2897363011A5069540694 @default.
• W2897363011 hasAuthorship W2897363011A5071952793 @default.
• W2897363011 hasAuthorship W2897363011A5073011726 @default.
• W2897363011 hasAuthorship W2897363011A5077251700 @default.
• W2897363011 hasAuthorship W2897363011A5078203831 @default.
• W2897363011 hasBestOaLocation W28973630111 @default.
• W2897363011 hasConcept C121608353 @default.
• W2897363011 hasConcept C126322002 @default.

• next